Catalent spikes as Barclays says FDA cleared Form 483 reports

Nov. 28, 2022 2:40 PM ETCatalent, Inc. (CTLT)RHHBY, SRPT, RHHBFBy: Dulan Lokuwithana, SA News Editor

FDA Headquarters - White Oak Campus


Contract manufacturer Catalent, Inc. (NYSE:CTLT) rose sharply on Monday after Barclays noted that the FDA over the weekend cleared both Form 483 observations related to the company’s Belgium and Bloomington facilities, removing a key overhang on shares.


Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.